Neurovalens
PrivateLast Round
VC Round
Aug 19, 2025
Total Funding Raised
$25.37M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Neurovalens operates in Healthcare & Life Sciences and is based in Belfast. Its latest recorded funding round was a VC Round in August 2025.
Neurovalens is a health-technology company that develops non-invasive neurostimulation products to address global health issues.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Health IoT, D2C Brands, Clinical Trials
Business Model
B2C
Customer Profile
Hardware Sales, Subscription SaaS
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neurovalens Comparables
Compare Neurovalens with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Flow Neuroscience | 84% | |
| Parasym | 83% | |
| Somnee | 80% |
For institutional investors. Book with your work email.
Neurovalens Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Aug 19, 2025 | ||||
| Early Funding | Aug 19, 2025 | ||||
| Series A Extension | Apr 8, 2024 | ||||
| Debt | Jan 21, 2022 | ||||
| Grant | Sep 1, 2021 | ||||
VC Round | Jul 20, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Neurovalens Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ACF Investors | VC Round, Early Funding |
| MedTech Innovator | Series A Extension |
| Future Fund | VC Round |
| Whiterock Finance | Debt, VC Round, Early Funding |
| British Business Bank | Series A Extension, Series A, Early Funding |
| Invest Northern Ireland | Series A Extension, Grant |
| IQ Capital | VC Round, Series A Extension, Series A, Early Funding, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 128% MoM.
- Jul 16, 2026
Grew 15% QoQ, from 26 to 30 employees.
For institutional investors. Book with your work email.
Neurovalens Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neurovalens's valuation, stock price, and market status.
Is Neurovalens a public or private company?
Neurovalens is a private company.
What is the current stock price of Neurovalens?
Neurovalens is a private company, so its shares have no public market price. Caplight tracks Neurovalens's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neurovalens worth (valuation)?
Valuation information for Neurovalens is not publicly available.
Can I buy Neurovalens stock?
Neurovalens shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neurovalens's last funding round?
Neurovalens's most recent funding round was VC Round on August 19, 2025.
Who are the main investors in Neurovalens?
Key investors in Neurovalens include IQ Capital.
Will Neurovalens IPO soon?
No public IPO plans have been announced for Neurovalens.
How can I track Neurovalens secondary market activity?
Caplight tracks bids, offers, and trades in Neurovalens's shares on secondary markets.